We are live on ! Find out more
CCM

Copernicus Capital Management Portfolio holdings

AUM $8.26M
1-Year Est. Return 37.91%
This Fund
S&P 500
This Quarter Est. Return
-6.34%
1 Year Est. Return
+37.91%
3 Year Est. Return
+125.98%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$107M
AUM Growth
-$4.93M
Cap. Flow
+$2.42M
Cap. Flow %
2.25%
Top 10 Hldgs %
84.05%
Holding
19
New
4
Increased
5
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$10.5M
2
ABBV icon
AbbVie
ABBV
+$9.05M
3
CNC icon
Centene
CNC
+$7.16M
4
IQV icon
IQVIA
IQV
+$4.98M
5
GILD icon
Gilead Sciences
GILD
+$3.27M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$5.88M
2
MRK icon
Merck
MRK
+$5.63M
3
ILMN icon
Illumina
ILMN
+$5.45M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$4.56M
5
SYK icon
Stryker
SYK
+$3.82M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$162B
$12.5M 11.67%
197,916
+50,000
+34% +$3.27M
VRTX icon
2
Vertex Pharmaceuticals
VRTX
$120B
$11M 10.22%
64,849
-6,000
-8% -$1.06M
BMY icon
3
Bristol-Myers Squibb
BMY
$126B
$10M 9.34%
197,937
-45,000
-19% -$2.11M
ABBV icon
4
AbbVie
ABBV
$454B
$9.99M 9.3%
+132,000
New +$9.05M
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$11.4B
$9.17M 8.53%
+136,000
New +$10.5M
IQV icon
6
IQVIA
IQV
$34.6B
$8.66M 8.06%
57,986
+32,000
+123% +$4.98M
TMO icon
7
Thermo Fisher Scientific
TMO
$213B
$8.44M 7.85%
28,976
-7,000
-19% -$2M
HUM icon
8
Humana
HUM
$47.4B
$7.93M 7.37%
31,000
-10,000
-24% -$2.8M
CNC icon
9
Centene
CNC
$31.5B
$6.36M 5.92%
+147,000
New +$7.16M
MRK icon
10
Merck
MRK
$322B
$6.23M 5.8%
77,552
-70,216
-48% -$5.63M
CDNA icon
11
CareDx
CDNA
$1.94B
$4.18M 3.89%
184,855
+55,000
+42% +$1.52M
ZTS icon
12
Zoetis
ZTS
$31.3B
$3.78M 3.52%
30,375
-20,000
-40% -$2.41M
ILMN icon
13
Illumina
ILMN
$29.8B
$2.83M 2.64%
9,577
-18,504
-66% -$5.45M
FOLD
14
DELISTED
Amicus Therapeutics
FOLD
$2.69M 2.5%
335,000
+10,000
+3% +$109K
SIEN
15
DELISTED
Sientra, Inc.
SIEN
$2.5M 2.32%
38,500
+2,500
+7% +$159K
FATE icon
16
Fate Therapeutics
FATE
$294M
$1.17M 1.08%
+75,000
New +$1.44M
ISRG icon
17
Intuitive Surgical
ISRG
$119B
– –
-33,603
Closed -$5.88M
SRPT icon
18
Sarepta Therapeutics
SRPT
$1.68B
– –
-30,000
Closed -$4.56M
SYK icon
19
Stryker
SYK
$122B
– –
-18,597
Closed -$3.82M

Similar funds

AAM
Areion Asset Management Hong Kong $7.82M AUM 16% 1-Year Est. Return
IR
Invictus RG Hamilton, Bermuda $8.9M AUM 56.32% 1-Year Est. Return
YEPV
Yorktown Energy Partners VI New York $6.21M AUM 74.4% 1-Year Est. Return
LC
Lunia Capital Dallas, Texas $4.49M AUM 42.82% 1-Year Est. Return
MA
MANA Advisors New York $3.06M AUM 7.13% 1-Year Est. Return
IFC
Intact Financial Corporation Toronto, Ontario, Canada $14M AUM
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Copernicus Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Copernicus Capital Management held 19 positions worth $107M, down 4.4% from $112M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Copernicus Capital Management's Q3 2019 filing shows 4 new, 5 increased, 7 reduced and 3 closed positions. Its largest new stake was BioMarin Pharmaceuticals: 136,000 shares worth $9.17M. The largest sale was Intuitive Surgical, an estimated $5.88M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Copernicus Capital Management's largest Q3 2019 buy was BioMarin Pharmaceuticals: 136,000 shares worth $9.17M.
  • Copernicus Capital Management added most to IQVIA in Q3 2019, an estimated $4.98M increase.
  • Copernicus Capital Management's biggest Q3 2019 reduction was Merck, cutting an estimated $5.63M.
  • Copernicus Capital Management fully exited Intuitive Surgical in Q3 2019, selling an estimated $5.88M.
  • Copernicus Capital Management's ten largest holdings make up 84% of its $107M portfolio in Q3 2019.
  • Copernicus Capital Management opened 4 new positions and closed 3 in Q3 2019.
  • Copernicus Capital Management's portfolio value fell 4.4% quarter-over-quarter to $107M.

Based on Copernicus Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.